reports
- Hilde Van Boxstael
- Jacob Mekhael
- Lynn Hautekeete
- Michiel Declercq
- Jacob Mekhael
MaaT Pharma Partnership with Clinigen secures MaaT013's EU commerciali...
MaaT signed a licensing, distribution, and commercial supply agreement with Clinigen in Europe for Xervyteg (MaaT013, microbiome therapy, enema formulation) in aGvHD for a € 10.5m upfront, € 18m in milestones, and mid-thirties flat royalty on sales. We believe this deal serves as validation of MaaT013's potential, and see the partnership as a de-risking event for MaaT013's commercialisation in Europe, given Clinigen's experience commercialising in haemato-oncology, with 3 products currently on t...
- ING Helpdesk
- Hans D’Haese
- Maxime Stranart
Colruyt/Divestment of loss-making French activity/BUY
We reiterate our BUY on Colruyt but reduce our target price from €45.5 to €44 following Colruyt's FY24/25 results. We believe that the competitive environment should improve for Colruyt in the upcoming months, noting (1) we lap tough comps on competitors opening stores on Sundays; (2) Colruyt will open its 146 OKay stores on Sunday as of early 2026, thanks to a change in Belgian regulation; and (3) reduced GDP growth forecasts in Belgium, which should benefit discounters. Valuation remains undem...
Colruyt Group N.V: 1 director
A director at Colruyt Group N.V bought 10,750 shares at 36.900EUR and the significance rating of the trade was 90/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cle...
- Kristof Samoy
- Livio Luyten
- Michiel Declercq
- Wim Lewi
- Michiel Declercq
Colruyt On the right track, but challenges remain
Last week, Colruyt published its FY24/25 results. While the results were in line with expectations, the outlook disappointed on the back of a challenging competitive environment. Despite the ongoing difficulties, we welcome the recently signed agreement to divest around 80% of its French stores. We expect that a full exit from the French market will enhance margins by around 40–50 basis points in FY26/27. Additionally, the transaction multiple is in line with market valuations. Incorporating the...
- Jean Danjou
- Jean Danjou
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Thomas Couvreur
- Jacob Mekhael
MaaT Pharma Business update highlights upcoming priorities, final ARES...
MaaT provides a business update, which reiterated the company's progress with respect to its pipeline, and following the previously announced EU regulatory submission for MaaT013 in aGvHD, the company continues to search for a commercialisation partner in Europe ahead of a potential approval in 2H26. Timeline for MaaT013 US trial launch shifts to 2026 (from 4Q25) to focus resources on the European opportunity. Looking ahead, data updates for MaaT013 in aGvHD (final results incl. 12-month OS), as...
- Robert Jan Vos
- Michiel Declercq
- Michiel Declercq
Colruyt FY24/25 results in line, reaches agreement for most of its Fre...
Despite only being expected after market, Colruyt already published its FY24/25 results this morning. Overall, the FY24/25 results were in line with our expectations after the group issued a profit warning early May. In FY24/25, group sales increased 1.1% but declined 0.4% on a comparable basis to € 10963m (kbcse: € 10999m) while the EBIT decreased by 5.0% to € 446m (kbcse: € 448m). Additionally, the group announced that it has reached an agreement to sell 81 of French stores for a cash consider...
- ING Helpdesk
- Emira Sagaama
- Jeremy Garnier
- Martial Descoutures
DGE DIAGEO PLC
RNO RENAULT SA
RI PERNOD RICARD SA
NXI NEXITY SA CLASS A
RCO REMY COINTREAU SA
UNIQA INSURANCE GROUP AG
BLC BASTIDE LE CONFORT MEDICAL SA
KCO KLOECKNER & CO SE
ALTR ALTRI SGPS SA
SWP SWORD GROUP SE
CGM CEGEDIM SA
COLR ETABLISSEMENTEN FRANZ COLRUYT N.V.
EKI EKINOPS SA
VLS VALNEVA SE
LNA LNA SANTE SA
JCQ JACQUET METALS SA
VNA VONOVIA SE
ELG ELMOS SEMICONDUCTOR SE
ALCAR CARMAT SA
TPE PVA TEPLA AG
QDT QUADIENT SA
IMPN IMPLENIA AG
IDIP INSTITUT DE DEVELOPPEMENT INDUSTRIEL SCA
COR CORTICEIRA AMORIM SGPS SA
HEIJM HEIJMANS N.V. CERT
PAL
RIEN PALFINGER AG
AMG RIETER HOLDING AG
EDR AMG ADVANCED METALLURGICAL GROUP N.V.
ZAG EDREAMS ODIGEO SA
POST ZUMTOBEL GROUP AG
INSD OSTERREICHISCHE POST AG
FACC VERIMATRIX SA
AXS FACC AG
HBH ACCSYS TECHNOLOGIES
TRE HORNBACH HOLDING AG & CO. KGAA
SMCP TECNICAS REUNIDAS SA
BFSA SMCP SA
VOS BEFESA SA
BESI VOSSLOH AG
CAF BE SEMICONDUCTOR INDUSTRIES N.V.
MEDCL CONSTRUCCIONES Y AUXILIAR DE FERROCARRILES S.A.
EAT MEDINCELL SA
GRE AMREST HOLDINGS SE
ALCUR GRENERGY RENOVABLES
FQT ARCURE SA
CLA FREQUENTIS AG WIENER
S30 CLARANOVA SE
ALHGR SOLUTIONS 30 SE
BNTX HOFFMANN GREEN CEMENT TECHNOLOGIES SA
NACON BIONTECH SE
CPR NACON SASU
KTA DAVIDE CAMPARI-MILANO N.V.
UPG KNAUS TABBERT
ALAFY UNIFIEDPOST GROUP
FORSE AFYREN
WAGA FORSEE POWER SA
EAPI WAGA ENERGY SA
ACAG EUROAPI
ARVEN AUSTRIACARD HOLDINGS AG
ORP ARVERNE GROUP SA
LOCAL ORPEA
SOLOCAL GROUP
- Emira Sagaama
- Martial Descoutures
- Jacob Mekhael
MaaT Pharma Updated MaaT013 aGvHD EAP data at EHA shows consistent out...
MaaT reported updated early access program (EAP) results for MaaT013 (microbiome therapy, enema formulation) in aGvHD at EHA, being held 12-15 June. The data, which was previously shared in the abstract last month, shows that the response rates and overall survival observed in the steroid refractory and ruxulitinib resistant subset of patients (n=70) are in line with what was observed in the phase 3 ARES trial. In our view, this points to the consistency of outcomes with MaaT013 in this patient ...
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Michiel Declercq
- Thomas Vranken
- Wim Lewi
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.